関連する実験動画

Updated: May 8, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

CD4 (((+)) CD28null Tリンパ球の調節が,不安定性胸痛の患者における腫瘍死滅因子-アルファブロックによる

Vittoria Rizzello¹, Giovanna Liuzzo, Salvatore Brugaletta

¹Cardiology Department, Catholic University, Rome, Italy.

|May 10, 2006

まとめ

インフリキシマブによる腫瘍死滅因子アルファ (TNF-alpha) 阻害は,不安定な胸痛患者の攻撃的なCD4 (((+)) CD28null T細胞を減少させた. これは,TNF-α阻害が心血管疾患における炎症を調節する可能性があることを示唆している.

科学分野:

免疫学免疫学とは
心臓病学心臓病学
炎症炎症炎症炎症炎症

背景:

腫瘍死滅因子アルファ (TNF-alpha) は,CD4とCD28のゼロT細胞の拡張を促進する.
このT細胞のサブセットは,不安定なアンギナ (UA) の攻撃的な炎症に関連しています.

研究の目的:

選択的なTNF-α阻害がUA患者における炎症を調節できるかどうかを調査する.

主な方法:

17人のUA患者からの周辺血液は,インフリキシマブ (抗-TNF-α抗体) のさまざまな用量で化されました.
CD4(+) CD28null T細胞の割合とCD4+ T細胞のCD28発現はフローサイトメトリーで分析した.

主要な成果:

インフリキシマブは,CD4 (((+)) CD28null T細胞の割合を著しく低下させました.
インフリキシマブの投与量の増加は,CD4+T細胞におけるCD28発現の有意な増加につながった.

結論:

選択的なTNF-α阻害は,UA患者におけるCD4 (((+)) CD28null T細胞の拡張を有効に減少させる.
CD4 ((+)) CD28null T細胞の調節による臨床的利益を決定するために,さらなる研究が必要である.

さらに関連する動画

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

Published on: June 7, 2017

An In Vivo Mouse Model to Measure Naïve CD4 T Cell Activation, Proliferation and Th1 Differentiation Induced by Bone Marrow-derived Dendritic Cells

An In Vivo Mouse Model to Measure Naïve CD4 T Cell Activation, Proliferation and Th1 Differentiation Induced by Bone Marrow-derived Dendritic Cells

Published on: August 22, 2018

関連する概念動画

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...